Cell Surface Markers Market Size, Trends and Industry Outlook by Product (Antibody, PCR Array), by Source (Mice, Rat), by Cell Type (T Cells, B Cells, NK Cells), by Application (Research (Stem Cell, Immunology), Clinical (Oncology, Hematology)) - Global Forecast Till 2030

ID: MRFR/HC/5941-HCR | 90 Pages | Published By Kinjoll Dey on March 2023

Speak to Analyst Request a Free Sample

Cell Surface Markers Market

Cell Surface Markers Market size is expected to register a CAGR of 7.8 % and was valued at USD 651.42 Million.

$651.42 Million

Market Size

7.8%

CAGR

North America

Dominating Region

2022-2030

Forecast Period

Segmentation

Key Players

Companies Profiled • Bio-Rad Laboratories • Inc. • Abbott • Siemens Healthcare Private Limited • Beckman Coulter • Inc. • F. Hoffmann-La Roche Ltd • NIHON KOHDEN CORPORATION • Thermo Fisher Scientific • BD • Abcam plc. • QIAGEN • Danaher • GenScript • Merk KGaA • BioLegend • Inc. • Cell Signaling Technology • Inc. • Bio-Techne and Others.

Drivers

Request a Free Sample

Cell Surface Markers Market Overview

The cell surface markers market is expected to reach USD 651.42 Million by 2030 at 7.8% CAGR during the forecast period 2022-2030. These are found on the surface of the specific cell types, and they can determine antigen and protein in the particular cell type. To identify the type of cell, this acts as a marker and is helpful in the time of identification. Several growth factors can have a good impact on the market. The factors include advancements in healthcare technologies declining in the healthcare expenditure as a rule by the government by reducing the diagnosis cost are expected to boost the market in the forecast period. The complex products and high price of the instruments and reagents in cell markers analysis will hinder the market in the forecast period. The rising demand for effective drugs against chronic diseases is leading the market. The continuous manufacturing of the new medicines and development of therapies like immunotherapy, stem cells, etc., will drive the market. The use of the biotechnology and pharmaceutical industries for research is creating ample opportunities for the market.

Cell Surface Markers Market Segmentation

The global cell surface markers market has been segmented into product, source, cell type and applications.

The market, on the basis of product, has been segmented into antibody and PCR array.

The market, by source, has been segmented into mice, rat and others.

The cell surface markers market, by cell type, has been segmented into T cells, B cells and NK cells.

The market, by applications, has been segmented into research, clinical and others. Research segment has been further divided into stem cell and immunology. Clinical segment is further divided into oncology and hematology. Research segment is expected to hold the largest market share owing to wide use in pharmaceutical research. Clinical segment is anticipated to grow at the fastest CAGR owing to rising applications in the segment.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The cell surface markers market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The cell surface markers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Global Cell Surface Markers Market Share (%), by Region, 2017

Cell Surface Markers Market

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports

Geographically, the Americas is anticipated to dominate the global cell surface markers market owing to the significant amount of research and development activities in the region and rising healthcare expenditure. For instance, according to U.S. Centers for Medicare & Medicaid Services, in 2017, healthcare spending in US increased 3.9% to reach USD 3.5 trillion or USD 10,739 per person. Europe is expected to hold the second largest position in the global cell surface markers market. The market growth in this region is attributed to the rising funding for life science research. The cell surface markers market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and the Rest of the Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the rising number of diagnostic laboratories and government initiative towards research centers. For instance, according to the Australian Institute of Health and Welfare, during 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health. The Middle East & Africa are expected to grow at a slow rate owing to a developing healthcare infrastructure.Recent Development

May 2022

Multiplex immunofluorescence can reveal cellular phenotypes and interactions within the tumor microenvironment with whole-slide spatial context and single-cell resolution.

April 2022

Immune Cell-Based Kits iQue® enable the analysis of several immunological cell phenotypes and functional traits like viability, proliferation, and cytokine release. Most of these kits are improved for low-wash protocols.

The new study was published on April 13 in the Science Advances. It shows in mice with leukemia that this nibble sometimes comes with a side of PD-1. This protein inhibits NK cell activity, allowing the cancer cell to escape.

Recent research revealed that mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity.

Global Cell Surface Markers Market, by Product

Antibody

PCR Array

Global Cell Surface Markers Market, by Source

Mice

Others

Global Cell Surface Markers Market, by Cell Type

T Cells

B Cells

NK Cells

Global Cell Surface Markers Market, by Applications

Research
- Stem Cell
- Immunology

Clinical
- Oncology
- Hematology

Others

Global Cell Surface Markers Market, by Region

Americas
- North America
  - US
  - Canada
- South America

Europe
- Western Europe
  - Germany
  - France
  - Italy
  - Spain
  - UK
  - Rest of Western Europe
- Eastern Europe

Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

The Middle East & Africa
- Middle East
- Africa

Global Cell Surface Markers Market, by Key Players

Bio-Rad Laboratories, Inc.

Siemens Healthcare Private Limited

Beckman Coulter, Inc.

NIHON KOHDEN CORPORATION

Hoffmann-La Roche Ltd

Abcam plc.

QIAGEN

Thermo Fisher Scientific

Abbott

Danaher

GenScript

Merk KGaA

BioLegend, Inc.

Cell Signaling Technology, Inc.

Bio-Techne

Intended Audience

Research and Development Organization

Biotechnology Companies

Healthcare Organizations

Academics and Research Institutes

Geographically, the Americas is anticipated to dominate the global cell surface markers market owing to the significant amount of research and development activities in the region and rising healthcare expenditure. For instance, according to U.S. Centers for Medicare & Medicaid Services, in 2017, healthcare spending in US increased 3.9% to reach USD 3.5 trillion or USD 10,739 per person. Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to the rising funding for life science research. The cell surface markers market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and the Rest of the Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the rising number of diagnostic laboratories and government initiative towards research centers. For instance, according to the Australian Institute of Health and Welfare, during 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health. The Middle East & Africa are expected to grow at a slow rate owing to a developing healthcare infrastructure.